PDPN and cancer: Although many anti-podoplanin MAbs have been produced, almost all anti-podoplanin MAbs react with a platelet aggregation-inducing (PLAG) domain of human podoplanin.(7,24–28) Rabbit polyclonal antibodies produced by immunizing recombinant rat podoplanin also recognize PLAG domains, which were shown to be immunodominant antigenic sites.(29) We recently established the platform to produce cancer-specific MAbs (CasMabs).(30) In this study, we produced and characterized a novel anti-podoplanin monoclonal antibody, LpMab-3, one of non-CasMabs.